Tag Archive for: BioPharma

Poolbeg Pharma plc: POLB 001 patent portfolio strengthened through granting of US patent

/in

Key highlights ·      Patent granted for use of certain p38 MAP kinase inhibitors for the treatment of hypercytokinaemia ·      Allows for use in combination with an antiviral agent ·      Patent enhances the robust IP portfolio protecting Poolbeg’s growing pipeline   8 March 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’),  a leading infectious disease focused biopharmaceutical company, announces that […]

Read more

Scrip Asks… What does 2023 hold for Biopharma?

/in

More than one hundred industry executives and experts provided insight into what to expect for the year ahead. Here’s what we’ve read so far… Technological Advances Today’s article explores the technological advances expected during 2023. Developments in data science and molecular biology drive expectations – for another year of breakthrough innovation in human therapeutics. However, […]

Read more

Poolbeg announces strategic expansion of POLB 001 into oncology

/in

Complements strong initial data from LPS challenge trial and is in line with stated objective at IPO to expand POLB 001 to additional indications Key Highlights ·      Newly filed patent application to protect use of POLB 001 for new oncology indication ·      Scientific findings indicate POLB 001 has the potential to dampen the pro-inflammatory […]

Read more

Evaluate Vantage shares biopharma predictions for 2023

/in

In this report, Amy Brown, Edwin Elmhirst and Joanne Fagg of Evaluate Vantage discuss the outlook for biopharma in 2023.  According to the team, there is hope for an improvement in 2023 after the trials of the last two years, although few are expecting a dramatic recovery.   Check out the Evaluate team’s thoughts on the […]

Read more

Poolbeg exclusively licences innovative oral delivery technology for metabolic syndrome related diseases

/in

Clinical trial to demonstrate technology can safely deliver GLP-1 to commence in H1 2023 Prof Brendan Buckley joins Poolbeg’s Scientific Advisory Board to guide clinical development of technology Licence expands Poolbeg’s existing exclusive licence to AnaBio’s oral vaccine delivery technology Investor Meet Company presentation on 14 December 2022 at 5:30pm Read more…

Read more